These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37306107)

  • 1. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.
    Shulman DS; Merriam P; Choy E; Guenther LM; Cavanaugh KL; Kao PC; Posner A; Bhushan K; Fairchild G; Barker E; Klega K; Stegmaier K; Crompton BD; London WB; DuBois SG
    Cancer Med; 2023 Jul; 12(14):15207-15216. PubMed ID: 37306107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.
    DuBois SG; Krailo MD; Glade-Bender J; Buxton A; Laack N; Randall RL; Chen HX; Seibel NL; Boron M; Terezakis S; Hill-Kayser C; Hayes A; Reid JM; Teot L; Rakheja D; Womer R; Arndt C; Lessnick SL; Crompton BD; Kolb EA; Daldrup-Link H; Eutsler E; Reed DR; Janeway KA; Gorlick RG
    J Clin Oncol; 2023 Apr; 41(11):2098-2107. PubMed ID: 36669140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
    Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
    J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
    Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.
    DuBois SG; Krailo MD; Lessnick SL; Smith R; Chen Z; Marina N; Grier HE; Stegmaier K;
    Pediatr Blood Cancer; 2009 Mar; 52(3):324-7. PubMed ID: 18989890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
    Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
    Oncologist; 2012; 17(3):321. PubMed ID: 22363068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
    Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
    BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.
    Akshintala S; Sundby RT; Bernstein D; Glod JW; Kaplan RN; Yohe ME; Gross AM; Derdak J; Lei H; Pan A; Dombi E; Palacio-Yance I; Herrera KR; Miettinen MM; Chen HX; Steinberg SM; Helman LJ; Mascarenhas L; Widemann BC; Navid F; Shern JF; Heske CM
    Clin Cancer Res; 2023 Sep; 29(17):3329-3339. PubMed ID: 37398992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
    Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
    Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
    Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
    Vlahovic G; Meadows KL; Hatch AJ; Jia J; Nixon AB; Uronis HE; Morse MA; Selim MA; Crawford J; Riedel RF; Zafar SY; Howard LA; O'Neill M; Meadows JJ; Haley ST; Arrowood CC; Rushing C; Pang H; Hurwitz HI
    Oncologist; 2018 Jul; 23(7):782-790. PubMed ID: 29572245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
    Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
    BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.
    Grohar PJ; Glod J; Peer CJ; Sissung TM; Arnaldez FI; Long L; Figg WD; Whitcomb P; Helman LJ; Widemann BC
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):645-652. PubMed ID: 28735378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
    Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
    Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
    van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
    Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
    Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
    Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
    Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
    Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
    Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
    Robertson JF; Ferrero JM; Bourgeois H; Kennecke H; de Boer RH; Jacot W; McGreivy J; Suzuki S; Zhu M; McCaffery I; Loh E; Gansert JL; Kaufman PA
    Lancet Oncol; 2013 Mar; 14(3):228-35. PubMed ID: 23414585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
    Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
    Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.